Long‐term patient‐reported outcomes from an open‐label safety and efficacy study of bosutinib in Philadelphia chromosome–positive chronic myeloid leukemia patients resistant or intolerant to prior therapy

相似書籍

• Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia
  由: Khoury, H J, et al.
  出版: (2018)
• Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib
  由: Brümmendorf, Tim H., et al.
  出版: (2015)
• Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
  由: Cortes, Jorge E., et al.
  出版: (2011)
• Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia
  由: Brümmendorf, Tim H., et al.
  出版: (2020)
• Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib
  由: Cortes, Jorge E., et al.
  出版: (2016)